3 breakthroughs in subcutaneous lipid lowering injections for 2026

adicionou um novo artigo Wellness

2026-01-19 13:22:18 -

The 2026 management of hyperlipidemia is undergoing a radical transformation as the pharmaceutical industry shifts from daily oral pills to biannual "vaccine-like" injections. While statins remain the backbone of therapy, a new wave of siRNA and monoclonal antibody therapies are providing options for the 30% of patients who are statin-intolerant or fail to reach their LDL targets. These...

0 Comentários 0 Compartilhamentos 196 Visualizações 0 Anterior